Journal September 16, 2026 5 min read

Semaglutide: mechanism of action

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist. This page sets out its identifiers, its receptor pathway, and the clinical research studies that examine its metabolic, cardiovascular and neuropsych

peptides-pro Editorial

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, a synthetic analogue of the endogenous incretin hormone GLP-1. It is also referred to in the literature as semaglutide injection, semaglutide 2.4 mg, and oral semaglutide 3 mg, depending on the formulation and the study context. The compound is a potent long-acting GLP-1 receptor agonist with outstanding therapeutic efficacy for type 2 diabetes and obesity, and its widespread clinical use has driven increasing demand for analytical techniques to identify it in pharmaceutical formulations and biological matrices [9]. The evidence block supplied for this page does not give a sequence, molecular formula or molecular weight, so none is stated here.

The work described on this page centres on the glucagon-like peptide-1 receptor (GLP-1R) and its downstream effects on insulin resistance, lipids, body weight and metabolic biomarkers.

Research Studies

Semaglutide and cardiometabolic risk after gestational diabetes

A postpartum study is evaluating immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). This is an effectiveness-implementation Hybrid Type 1 study using a randomized clinical trial design to evaluate the effectiveness and potential real-world integration of the intervention. A total of 226 postpartum individuals with recent GDM are randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, is assessed at 6 months postpartum. Participants subsequently enter a 6-month maintenance phase, during which semaglutide continuation, discontinuation, or initiation reflects patient and clinician decisions [1].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

Patients with schizophrenia on second-generation antipsychotics carry a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options. A multicentre, double-blind, placebo-controlled randomised trial is evaluating whether adjunctive oral semaglutide 3 mg once daily, added to treatment as usual, reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability [2].

Semaglutide and muscle preservation in older adults

A randomized, double-blind, placebo-controlled trial is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [3].

Semaglutide and switching to zovaglutide in adults with obesity

The HORIZON-SWITCH-SZ study is evaluating the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity [4].

Semaglutide dose effects on craving and alcohol use outcomes

A study is examining two doses of semaglutide, 1.0 mg and 2.0 mg, versus placebo in patients with alcohol use disorder (AUD) and obesity (Ob), to assess whether these doses improve alcohol craving, stress and alcohol use outcomes [5].

Semaglutide and zenagamtide in excess body weight

A research study is investigating how well the medicine zenagamtide helps people with excess body weight lose weight compared to semaglutide [6].

Semaglutide reinitiation after sleeve gastrectomy in youth

A Phase 3a, randomized, parallel-controlled trial is comparing early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial involves 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants are randomized to either semaglutide 2.4 mg weekly or standard care for 24 months. Primary, secondary, and tertiary outcomes are assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. The investigators hypothesize that early re-initiation of semaglutide will be safe [7].

Semaglutide and structured lifestyle support in breast cancer survivors

A phase IV trial is studying whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor. In postmenopausal BCS taking an aromatase inhibitor, obesity raises the risk of heart and blood vessel problems. Semaglutide is a medicine approved by the United States Food and Drug Administration for weight loss and for lowering the risk of heart events in people with heart disease. The structured lifestyle support in this trial includes counseling on nutrition and physical activity which provides specific recommendations for individuals to follow [8].

Semaglutide treatment patterns and experienced effects

A community pharmacy-based cross-sectional survey investigated semaglutide treatment patterns among adult users in Denmark. Users of semaglutide for weight management (SEMA-WM) may not follow the recommended treatment regimen. A questionnaire-based survey was conducted across 28 Danish community pharmacies between March and May 2025 [10].

Semaglutide and neuropsychiatric outcomes

Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus (T2DM) and obesity. However, whether risks differ across successive generations of incretin-based therapies remains uncertain [11].

Semaglutide and gallbladder-related adverse events

A pooled analysis of placebo-controlled STEP trials examined gallbladder-related adverse events with semaglutide 2.4 mg [12].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.